ReviewJournal of personalized medicine2022
Asthma with Fixed Airflow Obstruction: From Fixed to Personalized Approach.
Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Add-on mepolizumab in patients with severe asthma on medium-dose inhaled corticosteroids.ERJ open research · 2026Article
- Clinical Characteristics of Geriatric Asthma in Guangxi of China: A Retrospective Comparative Descriptive Study.Aging medicine (Milton (N.S.W)) · 2026Article
- Persistent Airflow Limitation in Asthma: Clinical Characteristics, Risk Factors, and Long-term Outcomes from a Multicenter Cohort Study.Journal of asthma and allergy · 2026Article
- Analyzing soluble and lung smooth muscle laminin isoform expression in guinea pigs exhibiting various allergic response phenotypes.Frontiers in immunology · 2026Article
- COPD-Asthma-Heart Failure Overlap: Optimizing Bronchodilators and ICS in a High-Risk Triad.Journal of asthma and allergy · 2026Review
- Fixed airway obstruction and bronchodilator responsiveness phenotypes in severe asthma population from SANI registry.BMJ open respiratory research · 2025Article
- EPAS1 amplifies asthma pathogenesis through JAK2/STAT3-mediated ferroptosis and inflammation.Biomolecules & biomedicine · 2025Article
- Peripheral blood miRNAs are associated with airflow below threshold in children with asthma.Respiratory research · 2025Article
- A Multifaceted Exploration of Status Asthmaticus: A Retrospective Analysis in a Romanian Hospital.Journal of clinical medicine · 2024Article
- Risk factors for chronic obstructive pulmonary disease (COPD) in a tertiary health institution in Lagos, Nigeria.Ghana medical journal · 2023Article
- Article
- NJK14047 Suppression of the p38 MAPK Ameliorates OVA-Induced Allergic Asthma during Sensitization and Challenge Periods.Biomolecules & therapeutics · 2023Article
- Targeting inflammation or remodeling in asthma? Is there a right way?Frontiers in medicine · 2023Article
- Asthma: From Phenotypes to Personalized Medicine.Journal of personalized medicine · 2022Article
- Asthma and Tobacco Smoking.Journal of personalized medicine · 2022Review
- Asthma-COPD Overlap Syndrome: Recent Insights and Unanswered Questions.Journal of personalized medicine · 2022Review
- Association Between Medication Adherence and Risk of COPD in Adult Asthma Patients: A Retrospective Cohort Study in Canada.Clinical epidemiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is generally characterized by variable symptoms such as dyspnea and wheezing and variable airflow obstruction. This review focuses on a subset of patients suffering from asthma with persistent airflow limitation that is not fully reversible (asthma with fixed airflow obstruction, FAO). The pathophysiology, the risk factors and the clinical outcomes associated with FAO are presented, as well as the distinct clinical entity of severe asthma and its inflammatory subtypes (T2 and non-T2). The current strategies for the treatment of these endotypes and treatment of the distinct Asthma/COPD overlap (ACO) phenotype are described. Management and medical interventions in FAO and/or ACO patients demand a holistic approach, which is not yet clearly established in guidelines worldwide. Finally, a treatment algorithm that includes FAO/ACO management based on pharmacological and non-pharmacological treatment, guideline-based management for specific co-morbidities, and modification of the risk factors is proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.